Back to results
US 9,956,243 B2Granted
Combination treatment for acute myeloid leukemia (AML)
AssigneeHoffmann-La Roche Inc.
InventorsBrian Higgins, Gwen Nichols, Kathryn E. Packman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction such as, for example: and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer.
Claims13
A pharmaceutical product, comprising a) as a first component an inhibitor of the MDM2-p53 interaction;
- and b) as a second component cytarabine, wherein the inhibitor of the MDM2-p53 interaction is a compound of formula (I):
- wherein n is from 3 to 70;
- or a compound of formula (A):
A pharmaceutical product, comprising, a) as a first component a compound of formula (I):
- wherein n is from 3 to 70;
- and b) as a second component the compound cytarabine, wherein the dose of the compound of formula (I) corresponds to a dose of compound (A):
- within the range from about 200 to about 1600 mg/day.
Dependencies are inferred from the claim text.